Nonalcoholic Steatohepatitis (NASH) — Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Citation(s)
A Phase II, Multi-center, Two-Part, Three-Arm, Dose-Ranging Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)